PPT-NRTI-sparing

SPARTAN PROGRESS RADAR NEAT001ANRS 14 3 A4001078 VEMAN MODERN A4001078 Study ATVr MVC vs ATVr TDFFTC Design 16 years HIV Antiretroviral naive HIV1 RNA 1 000 c. Jim Demarest. ,. 1. Mark Underwood,. 2. Marty St Clair,. 2. . David Dorey,. 3. Steve Almond,. 3. Robert Cuffe,. 4. . Dannae Brown,. 5. Garrett Nichols. 6. . 1. ViiV Healthcare, Global R&D, Research Triangle Park, NC, USA; . Are NRTI’s Necessary?. Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, NW AETC ECHO. Last Updated: 1/22/15. NRTI-Sparing Regimens: Outline. Treatment initiation. Vincent Marconi, . MD. Outline. Transmitted Drug Resistance. Acquired Drug Resistance. Transmitted Drug Resistance. Europe. North America. Japan. Australia. Europe. 23K . pts. from 75 studies in 20 countries. Memantine. and IMRT Planning for Hippocampus Sparing in Patients Receiving Whole Brain Radiotherapy for Brain Metastases . Alexander Slade, PhD and Sinisa Stanic, MD. Carle Cancer Center and University of Illinois College of Medicine at Urbana-Champaign. EFV vs LPV/r vs EFV + LPV/r . A5142. Mexican. . Study. NVP vs ATV/r . ARTEN . EFV vs ATV/r . A5202. DOR vs DRV/r. DRIVE-FORWARD. Design. Objective. Non inferiority of DOR at W48: % HIV RNA < 50 c/mL by intention to treat, . David Spach, MD. Principal . Investigator, NW AETC. Professor of Medicine, Division of Infectious Diseases. University of . Washington. Last Updated: June 8, 2015. NRTI Resistance: Outline. Mechanism of NRTI Resistance. Treatment: . Is there an Analogy to Female Pelvic Cancer?. Ege Can Serefoglu, MD, . FECSM. UroKlinik. , . Istanbul. , . Turkey. 1. Outline. Cancer. . Treatment. . and. . Sexual. . Dysfunction. Prostate Cancer and Sex. Chief, Division of Infectious Diseases. Weill Medical College of Cornell University. New York, New York. Antiretroviral Therapy: . New Drugs and New Guidelines. FORMATTED: . 03/08/16. Chicago, Illinois: May 9, 2016. Drew Lambert, . PharmD. lambertd@husson.edu. Husson University School of Pharmacy. 1. PollEverywhere. - Text . DREWLAMBERT221 to 22333 to join. You . can respond at . PollEv.com/drewlambert221. I have no conflicts of interest.. ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N = 133. Continuación ATV/r 300/100 mg QD 2 NRTI . Diseño. Randomización. 1:1. Etiqueta abierta. Objetivo. Endpoint. primario: proporción de pacientes sin fallo al tratamiento a S48 . Medical Director, Specialty . Services. Southwest CARE Center. Santa Fe, New Mexico. State-of-the-ART. . in . Antiretroviral . Management. FORMATTED: MM/DD/YY. New Orleans, Louisiana: December 15-17, 2015. WHO HQ. The role of DTG based regimens in first- and second-line HIV treatment and PEP – Updated WHO recommendations. HIV testing and care continuum (2017). Source: UNAIDS/WHO . estimates. 2016 WHO recommandations for 1st Line ART in . Dolutegravir based regimens in first- ad second-line HIV Treatment. Meg . Doherty,. MD, PhD, MPH. WHO Geneva. Sunday 21 July, 2019. Increase in people receiving ART over time . (62% ART coverage). Source: UNAIDS/WHO . RADAR. NEAT001/ANRS 14. 3 . A4001078. VEMAN. MODERN. Kozal MJ. HIV Clin Trials 2012. ;13;119-30. Design. Efficacy endpoint. Primary : HIV RNA < 50 copies/. mL. at week 24 by . mITT. . (confirmed .